| 2.2 -0.04 (-1.79%) | 04-09 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 3.3  |
1-year : | 3.86 |
| Resists | First : | 2.82 |
Second : | 3.3 |
| Pivot price | 2.01  |
|||
| Supports | First : | 1.96 |
Second : | 1.42 |
| MAs | MA(5) : | 2.11 |
MA(20) : | 2.11 |
| MA(100) : | 2.06 |
MA(250) : | 1.35 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 75.9 |
D(3) : | 63.9 |
| RSI | RSI(14): 51.2 |
|||
| 52-week | High : | 3.81 | Low : | 0.56 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ IBIO ] has closed below upper band by 23.2%. Bollinger Bands are 23.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 2.26 - 2.27 | 2.27 - 2.28 |
| Low: | 2.12 - 2.14 | 2.14 - 2.15 |
| Close: | 2.18 - 2.2 | 2.2 - 2.22 |
iBio, Inc., a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States. The company operates in two segments: Biopharmaceuticals and Bioprocessing. Its lead therapeutic candidate is IBIO-100 that is being advanced for investigational new drug development for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis. The company is also developing vaccine candidates comprising IBIO-200 and IBIO-201, which are in preclinical development for the prevention of severe acute respiratory syndrome coronavirus 2; and IBIO-400 for the treatment of classical swine fever. In addition, it is developing recombinant proteins for third parties on a catalog and custom basis; and offers a range of process development, manufacturing, filling and finishing, and bio analytic services. iBio, Inc. has a license agreement with Planet Biotechnology, Inc. to develop therapeutics for infectious diseases; collaboration agreement with The Texas A&M University System for the development of coronavirus disease 2019 vaccine candidates; license agreement with the University of Natural Resources and Life Sciences, Vienna; and collaboration agreement with CC-Pharming Ltd. The company is headquartered in Bryan, Texas.
Thu, 09 Apr 2026
IBIO: Chardan Capital Maintains 'Buy' Rating with $5.00 Price Ta - GuruFocus
Thu, 09 Apr 2026
Ibio’s IBIO-600 cleared to enter clinic in Australia for obesity - BioWorld News
Thu, 09 Apr 2026
iBio Received Regulatory Clearance to Initiate Its Phase 1 Clinical Trial of IBIO-600 in Australia - Sahm
Wed, 08 Apr 2026
IBIO stock is soaring today after iBio's muscle-preserving drug receives approval for human trial in Australia - MSN
Wed, 08 Apr 2026
iBio Advances to Clinical Stage With IBIO-600 Trial - TipRanks
Wed, 08 Apr 2026
Regulators clear iBio (NASDAQ: IBIO) to launch first-in-human IBIO-600 trial - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 35 (M) |
| Held by Insiders | 2.702e+007 (%) |
| Held by Institutions | 2.4 (%) |
| Shares Short | 4,180 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -2.474e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -8 % |
| Return on Assets (ttm) | 491 % |
| Return on Equity (ttm) | -37 % |
| Qtrly Rev. Growth | 300000 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | -57.09 |
| EBITDA (p.s.) | 243902 |
| Qtrly Earnings Growth | -1 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -19 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.04 |
| Price to Cash Flow | 1.43 |
| Dividend | 0 |
| Forward Dividend | 4.19e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|